Welcome to our dedicated page for Opus Genetics news (Ticker: IRD), a resource for investors and traders seeking the latest updates and insights on Opus Genetics stock.
Opus Genetics, Inc. develops ophthalmic therapies for inherited retinal diseases as a clinical-stage biopharmaceutical company. Its pipeline includes AAV-based gene therapy programs led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1 and MERTK.
Company news commonly covers clinical and preclinical data, FDA regulatory interactions, scientific conference presentations, financing arrangements and annual financial results. Updates also include ophthalmic small-molecule development tied to Phentolamine Ophthalmic Solution 0.75% and collaboration activity related to that asset.
Opus Genetics (Nasdaq: IRD) agreed to a $25.0 million private placement of 7,374,632 shares of Series B Non‑Voting Convertible Preferred Stock at $3.39 per share. The preferred stock is expected to automatically convert one-for-one into common stock, subject to shareholder approval to increase authorized shares.
The financing is led by Adage Capital Management with participation from Trails Edge Capital Partners and Marshall Wace, is expected to close on February 18, 2026, and proceeds will fund gene therapy programs, working capital and general corporate purposes. Opus Genetics expects year-end 2025 pro forma cash of $70 million, which it says should fund operations into the first half of 2028.
Opus Genetics (Nasdaq: IRD) announced leadership participation in multiple ophthalmology and industry conferences in February 2026, presenting clinical and manufacturing updates.
Events include CCOI (Feb 3-4, Hong Kong), APAO (Feb 5-8, Hong Kong), Advanced Therapies Week (Feb 11, San Diego) and Macula Society (Feb 27, San Diego).
Opus Genetics (Nasdaq: IRD) launched a clinical trial for OPGx-MERTK, an AAV-based gene therapy for MERTK-related retinitis pigmentosa, with funding from Abu Dhabi’s Healthcare Research and Innovation Fund.
Cleveland Clinic Abu Dhabi will serve as the clinical site and clinical development activities are expected to commence in 2026. The program targets a disease affecting an estimated 60,000 patients worldwide and addresses an area with no approved treatments.
Opus Genetics (Nasdaq: IRD) reviewed 2025 progress and outlined 2026 catalysts across its ophthalmic gene therapy pipeline. Key near-term milestones include 3-month cohort data from the Phase 1/2 BEST1 trial expected mid-2026, initiation of pivotal Phase 3 dosing for LCA5 in the second half of 2026 after positive Phase 1/2 results, and an sNDA submission for a partnered presbyopia treatment with a regulatory decision anticipated by end of 2026. The company reported cash and cash equivalents of $30.8M as of Sept 30, 2025 and raised ~$23.0M in a subsequent registered direct offering, giving a cash runway into the second half of 2027 based on current plans. Multiple programs may qualify for Rare Pediatric Disease designation and other expedited pathways.
Opus Genetics (Nasdaq: IRD) announced on Dec 16, 2025 that its Compensation Committee approved an inducement equity award under the 2021 Inducement Plan to a newly hired non-executive employee in compliance with Nasdaq Listing Rule 5635(c)(4). The award consists of options to purchase 50,000 shares of common stock with an exercise price equal to the fair market value on the grant date.
The options vest over four years: 25% at one year and the remaining 75% in quarterly installments, subject to acceleration or forfeiture per the award agreement.
Opus Genetics (Nasdaq: IRD) announced that CEO George Magrath, M.D. will present at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026 at 8:15 a.m. PT.
The company is a clinical-stage biopharmaceutical developer of gene therapies for inherited retinal diseases. A live and archived webcast will be available on Opus Genetics' investor website under Events.
Opus Genetics (Nasdaq: IRD) announced that an Independent Data Monitoring Committee issued a positive recommendation to continue the Phase 1/2 BEST1 (BIRD-1) trial after a pre-specified safety review.
The IDMC reviewed one-month safety data from the sentinel participant in the multi-center, adaptive, open-label, dose-exploring study of OPGx-BEST1 in Best disease and recommended advancing enrollment and dosing without modification, enabling dosing of the next four participants.
The company framed the outcome as an encouraging early safety signal that supports continued clinical evaluation of OPGx-BEST1 for Best disease.
Opus Genetics (Nasdaq: IRD) announced on Dec 2, 2025 that its Compensation Committee approved inducement equity awards under the company’s 2021 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards were granted to two new non-executive employees as options to purchase an aggregate of 124,000 shares of common stock. The options have an exercise price equal to the fair market value on the grant date and vest over four years: 25% at one year and the remaining 75% in quarterly installments, subject to acceleration or forfeiture as set in each award agreement.
Opus Genetics (Nasdaq: IRD) announced management will participate in two investor conferences in early December 2025. Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, will appear in a fireside chat at BTIG 5th Annual Ophthalmology Day (Virtual) on December 1, 2025 at 1:00 p.m. ET. George Magrath, M.D., Chief Executive Officer, will appear in a fireside chat at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 at 10:00 a.m. ET in New York.
A link to the live and archived webcast for the Piper Sandler presentation is available on Opus Genetics' Investors > Events web page.
Opus Genetics (Nasdaq: IRD) announced dosing of the first participant in the OPGx-BEST1 Phase 1/2 gene therapy trial for Best disease on Nov 13, 2025. The one-time subretinal injection therapy targets BEST1-mutant retinal pigment epithelium cells. The trial is led by Dr. Mark Pennesi with surgical teams at Retina Consultants of Texas. Initial clinical data are expected in Q1 2026.